Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Anti BCMA CAR T cell therapy-Carbiogene Therapeutics (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Carbiogene Therapeutics
- 29 Nov 2024 New trial record